Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Clinical research

Two peptides predict cardiomyopathy after brain haemorrhage

Swedish PhD student finds biomarkers that can identify subarachnoid haemorrhage patients at risk of cardiomyopathy.

Patients with subarachnoid haemorrhage (SAH) developing stress-induced cardiomyopathy (SIC), coloured x-ray pictured. Research found that these patients had higher peak levels of the cardiac damage peptides hsTnT and NTproBNP

Source: Alfred Pasieka / Science Photo Library

Stress-induced cardiomyopathy (pictured) could be predicted by analysing levels of two peptides in patients who had suffered subarachnoid haemorrhage

Patients with subarachnoid haemorrhage (SAH) – a type of stroke – are at risk of developing stress-induced cardiomyopathy (SIC), a condition in which the left ventricle of the heart becomes inactive. 

Research from the University of Gothenburg, Sweden, has identified two biomarkers that could predict patients most at risk[1]

PhD student Jonatan Oras studied 112 patients admitted to intensive care with SAH, of whom 25 developed SIC. Oras found that these patients had higher peak levels of the cardiac damage peptides hsTnT and NTproBNP. One to three days after onset of SIC, levels of these peptides were superior for predicting SIC than both ECG and X-ray. 

In animal models of SAH, Oras found that the anaesthetic isoflurane had a cardioprotective effect against the development of SIC. He suggests further research is conducted into isoflurane sedation for patients with SAH. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200198

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Dale and Appelbe's Pharmacy and Medicines Law

    Dale and Appelbe's Pharmacy and Medicines Law

    This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.

    £57.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • FASTtrack: Pharmaceutical Compounding and Dispensing

    FASTtrack: Pharmaceutical Compounding and Dispensing

    FASTtrack: Pharmaceutical Compounding and Dispensing helps the student compounder to understand the key dosage forms in extemporaneous dispensing.

    £25.00Buy now
  • FASTtrack: Applied Pharmaceutical Practice

    FASTtrack: Applied Pharmaceutical Practice

    FASTtrack: Applied Pharmaceutical Practice guides student pharmacists and pharmacy technicians through the main stages of pharmaceutical dispensing.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Patients with subarachnoid haemorrhage (SAH) developing stress-induced cardiomyopathy (SIC), coloured x-ray pictured. Research found that these patients had higher peak levels of the cardiac damage peptides hsTnT and NTproBNP

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.